Acute Lymphocytic Leukemia Therapeutics Market

SKU: DMPH2878 | Last Updated On: Oct 18 2022 | Available Formats

>Acute Lymphocytic Leukemia Therapeutics Market Expected to reach a high CAGR of 4.2% by 2029:

Acute Lymphocytic Leukemia Therapeutics Market is segmented By Drug (Existing Regimens/Drugs (Hyper-CVAD Regimen, CALGB 8811 Regimen, Linker Regimen, Nucleoside Metabolic Inhibitors (Clolar, Nelarabine), Oncaspar), Pipeline Drugs (Phase III) (Graspa, Marqibo, Inotuzumab Ozogamicin)), By Therapy (Targeted Drugs & Immunotherapy, Chemotherapy, Radiation Therapy, Stem Cell Transplantation), By Cell Type (Philadelphia Chromosome (Positive (Ph+), Negative (Ph-)), Precursor B-Cell ALL, T-Cell ALL), By Distribution Channel (Hospital Pharmacy, Pharmacy stores, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Acute Lymphocytic Leukemia Therapeutics Market is expected to grow at a high CAGR of 4.2% during the forecasting period (2022-2029). 

Acute Lymphocytic Leukemia Therapeutics Market Report Scope



Market CAGR


Segments Covered

By Drug,  By Therapy, By Cell Type, By Distribution  channel,  and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Regions Analyzed

North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.

Major Companies Covered

FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, MiMedx Group, Inc, and among other major companies listed in the full report

To know more insights into the Market, Get Our Sample Brochure

Acute Lymphocytic Leukemia also called lymphoblastic leukemia is cancer that starts from the early version of white blood cells called lymphoblastic in the bone marrow. Acute Lymphocytic Leukemia is characterized by the overproduction of cancerous lymphoblast’s. It spreads in the body through lymph nodes, the spinal cord, liver, the spleen, and central nervous system, among others.

North America region holds the largest market share global acute lymphocytic leukemia therapeutics market

North America is expected to dominate this market, due to the rising number of cases of this disease in the region, owing to genetic factors, environmental factors, and radiation. Moreover, favourable government policies, well-established healthcare infrastructure, and the presence of multinational companies make this region dominant in this market. For instance, the U.S. is anticipated to witness substantial growth due to the launch of the drug, besponsa (inotuzumab ozogamicin), in August 2017 and the presence of strong pipeline drugs such as eryaspase (asparaginase), which is under phase II of clinical trials.

Acute Lymphocytic Leukemia Therapeutics Market Growth Drivers, and Opportunities

The global acute lymphocytic leukemia therapeutics drugs market growth is driven by the increasing initiatives taken by the government and pharmaceutical organizations to spread awareness regarding the disease is also expected to foster the growth of the market. Moreover, advancements in technologies for the treatment of disorders that have been caused by rising investments undertaken by the manufacturers are also expected to drive the growth of the market.

The growing prevalence of acute lymphocytic leukemia is expected to drive growth in the forecast period  

The rising occurrence of acute lymphoblastic leukemia (ALL)  is the major factor responsible for the growth of this market globally. The number of new cases being recorded each year is around 1.7 per 100,000 men and women per year. It has been estimated by the American Cancer Institute that in 2019, there will be around 5,930 new cases of ALL i.e. 3,280 in males and 2,650 in females. In addition, by 2020, it has been estimated that the number of cases of ALL may range around 0.4 to 2 per 100,000 population in the Asia-Pacific and South American countries. There is a rise in the number of cases primarily due to the adoption of western lifestyles, including dietary changes and sedentary lifestyles. Moreover, globally, the prevalence is expected to increase during the forecast period, which shall be the major factor for the growth of this market.

Introduction of new drugs for Acute Lymphocytic Leukemia Therapeutics is projected, expected to drive the market growth

The technological advancements in the healthcare sector and the introduction of new drugs for acute lymphocytic leukemia therapeutics are projected to enhance the growth of the acute lymphocytic leukemia therapeutics market in the forecast period. Furthermore, the “Therapeutically Applicable Research to Generate Effective Treatments (TARGET)” initiative and “Childhood Cancer Targeted Therapeutics Workshop” have launched many programs and collaborated with many research groups across different countries such as St. Jude Children’s Research Hospital and the University of New Mexico etc., to provide facilities to patients for early diagnosis and better treatment of leukemia. These factors drive the market growth in the forecast period.

The high levels of expiration of patents associated with them are likely to hinder the market growth

However, the high levels of expiration of patents associated with the drugs already in the market are expected to restrain the growth of the market. Concerns regarding the reactions associated with the treatment options are also expected to restrict the growth of the market.

COVID-19 Impact Analysis

Since the emergence of the COVID-19 infection, many recommendations have been made. However, the very nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations, even if data for this population are still scarce. Recommend testing all patients for COVID-19 before any hospital admission and/or procedure, even in the absence of symptoms. In the setting of neutropenic fever with no other source or with abnormal chest radiology findings, consider testing for COVID-19 twice at least 12 hours apart to rule out true infection. Consider delaying treatment if possible for patients who test positive for COVID-19.

Although China is a major supplier of medications used in the world the interruptions in production that occurred in certain regions due to the COVID-19 outbreak there did not impact global supplies and normal production is being resumed as the number of cases these factors will hamper the growth of the market in the forecast period.

Acute Lymphocytic Leukemia Therapeutics Market Segmentation Analysis

The chemotherapy, segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)  

The growing prevalence of cancer worldwide and the presence of untapped opportunities in emerging economies, along with improving healthcare infrastructure in these regions are among the key trends stoking market growth. The American Cancer Association stated that chemotherapy is the main treatment for people suffering from acute lymphoblastic leukemia, and it has three phases, such as remission, consolidation, and maintenance. Chemotherapy uses cytotoxic drugs for the destruction of cancer cells.

Amsacrine (NordMedica), cyclophosphamide (Baxter), and cytarabine (Pfizer) are some of the drugs that are used for chemotherapy in acute lymphoblastic leukemia. Global pharmaceutical players, such as Baxter International, and Pfizer, are providing these drugs. Acute lymphoblastic leukemia is the most common cancer in children, adolescents, and young adults younger than 20 years, accounting for 19.8% of all cancer cases in this age group, as per a 2019 report by the Leukemia & Lymphoma Society. Hence, the market for chemotherapy is also expected to boost due to the high prevalence of acute lymphoblastic leukemia, especially among children.   

The hospital pharmacy is expected to dominate the acute lymphocytic leukemia therapeutics market during the forecast period

The hospital pharmacies held the largest share in the acute lymphocytic leukemia therapeutics market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Acute Lymphocytic Leukemia Therapeutics Market Competitive Landscape

The acute lymphocytic leukemia therapeutics market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Amgen Inc., Bristol-Myers Squibb Company, Erytech Pharma, Novartis AG, Pfizer Inc., Rare Disease Therapeutics, Inc., Sanofi, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the acute lymphocytic leukemia therapeutics market globally.    

Compeny Profile Overview

Amgen Inc

Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.

The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centres, hospitals, and pharmacies.

Product Portfolio: The Company’s portfolio is comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.

Key Development: In January 2019, Amgen Inc. announced that the European Commission had approved the expansion of indication for “BLINCYTO (blinatumomab) monotherapy” for treatment of adult patient group suffering from “Philadelphia chromosome-negative (Ph-) CD19 positive B-cell precursor acute lymphoblastic leukemia (ALL)” in remission stages first and second with MRD at 0.1 per cent or greater. This therapeutic is the first-ever immunotherapy that has been approved worldwide.

Frequently Asked Questions

What is the Projected CAGR value of the Acute Lymphocytic Leukemia Therapeutics Market?

Acute Lymphocytic Leukemia Therapeutics Market is expected to grow at a CAGR of 4.2% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Acute Lymphocytic Leukemia Therapeutics Market during 2022-2029

Which is the fastest growing region in the Acute Lymphocytic Leukemia Therapeutics Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period 

Trending Topics

Primary Peritoneal Cancer Therapeutics Market

Paraganglioma Treatment Market

Myeloproliferative Disorders Drugs Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!